BioSpace News Archive

AnX Robotica Corporation, the developer and manufacturer of the NaviCam® Magnetically Controlled Capsule Endoscopy System, is pleased to announce a partnership with GastroGPO, a Specialty Networks Company.

CMC Pharmaceuticals has been awarded a Sequential Phase II Small Business Innovation Research (“SBIR”) grant from the U.S. Defense Department’s (“DoD”) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Threat Reduction Agency.

Moves up 28 places from 2022 Agilent Technologies Inc. announced the company is ranked 101 in Newsweek’s 2023 list of America’s Most Responsible Companies, up 28 places from 2022.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA) today announced results from a Phase 1b dose escalation clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), in combination with palbociclib, a CDK 4/6 inhibitor for the treatment of metastatic ER+/HER2- breast cancer.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to two new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Rhythm Pharmaceuticals, Inc. announced that on December 2, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 29,925 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 19,950 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 9,975 shares of its common stock.

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported progress across its portfolio of novel GeneTAC™ small molecules. Today’s updates include initial results on DT-216 from the company’s single-ascending dose (SAD) Phase 1 clinical trial in patients with Friedreich ataxia (FA).

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 215,000 shares of the Company’s common stock on December 1, 2022.

Prometheus Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250 million of shares of its common stock in an underwritten public offering.

Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today that Congruence’s CEO, Dr. Clarissa Desjardins, will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 3:30 PM.